<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html><!-- InstanceBegin template="/Templates/submenus.dwt" codeOutsideHTMLIsLocked="false" -->
<head>
<!-- InstanceBeginEditable name="doctitle" -->
<TITLE>PNI.org | Pacific Neuropsychiatric Institute</TITLE>
<!-- InstanceEndEditable --> 
<META NAME="description" CONTENT="The Pacific Neuropsychiatric Institute
(PNI) is involved with comprehensive evaluation and management in
Neuropsychiatry and Psychopharmacology at the clinical, research,
forensic, education and phenomenologic levels.">
<META NAME="keywords" CONTENT="Vernon Neppe, medicine, psychopharmacology,
neuropsychiatry, forensic psychiatry, neuropsychiatric, institute,
education, lectures, brain, forensics, journal, internet journal, Neppe,
neurotransmitters, medical ethics, questionnaire, research instruments,
caffeine, philosophy, vortex pluralism, epileptology, anomalous, informed
consent, pharmacology, neuropsychology, clinical medicine, mental health,
brain injury, epilepsy, seizure, head injury, deja vu, anomalistic
experience, parapsychology, phenomenology, psychiatric, medical, drug,
BROCAS SCAN, STRAW, INSET, NMBPRS, PBRS, mental status, MMPI, SCL-90,
MMSE, Electroencephalogram, Electroencephalography, EEG, Ambulatory
monitoring, Ambulatory EEG, ventricular dilatation, MRI head, CT head,
SPECT head, PET head, competency, statistics, litigation, competence,
deposition, evidence, ethics, pharmacokinetics, pharmacodynamics, P450,
side-effects, tachyphylaxis, FDA, in vitro, in vivo, receptorology, civil
litigation, DSM, internet journal of Neuropsychiatry and
Psychopharmacology, JINEPP, INEPP, medical books, innovative
psychopharmacotherapy, partial agonist, agonist, antagonist, receptor,
synapse, autoreceptor, post-synaptic, pre-synaptic, down regulation, up
regulation, supersensitivity, subsensitivity, GABA, NMDA, receptor
subtypes, serotonin, norepinephrine, acetylcholine, benzodiazepine,
dopamine, opiates, chloride ionophore, pituitary, hypothalamus, temporal
lobe, frontal lobe, parietal lobe, occipital lobe, cerebral cortex,
kindling, chindling, bathtub, pushbuttons, motivation, MSE, mental status
examination, cognition, affect, volition, lesion localization,
psychomotor, dangerousness, environmental interaction, memory,
concentration, normality, organic brain syndrome, behavioral neurologist,
sleep, obesity, bariatric medicine, EMG, Electromyography, Nerve
conduction, antidepressant, anxiolytic, anxioselectivity, psychostimulant,
beta blocker, beta blockade, anticonvulsant, adjunctive therapy, appetite
suppressants, computer therapy, computerized diagnosis, memory retraining,
speech retraining, neuropharmacology, neuropharmacologist,
psychopharmacology, psychopharmacologist, anxiety, depression, OCD, ADD,
ADHD, attention deficit hyperactivity disorder, aggression, irritability,
tardive dyskinesia, movement disorder, neurology, Parkinson's, headache,
pain, sexual dysfunction, fibromyalgia, obsessive compulsive, Alzheimer's,
seizure, epilepsy, epileptic, TLE, CPS, closed head injury, CHIT, CHIP,
MTBI, PTSD, traumatic brain injury, methylphenidate, Ritalin, zolpidem,
Ambien, nadolol, Corgard, pemoline, Cylert, selegeline, nitrous oxide,
azapirones, phenytoin, Dilantin, topiramate, Topamax, tiagabine, Gabitril,
valproate, Depakote, felbamate, Felbatol, gabapentin, Neurontin,
carbamazepine, Tegretol, lamotrigine, Lamictal, neuroleptics, sumatriptan,
Imitrex, Sinemet, carbidopa, SSRI, sertraline, paroxetine, fluvoxamine,
fluoxetine, Zoloft, Paxil, Prozac, Luvox, bupropion, Wellbutrin, tricyclic
antidepressant, amitriptyline, imipramine, bromocriptine, Eldepryl,
Aricept, donepezil, pergolide, Cognex, tacrine, Parlodel, cyclobenzaprine,
Flexeril, phentermine, Buspar, buspirone, nefazodone, Serzone,
venlafaxine, Effexor, clozapine, Clozaril, perphenazine, Trilafon,
mirtazapine, Remeron, recreational drugs, firearms, cigarette, marijuana,
cannabinol, herbal remedies, St John's Wort, anti-oxidant,
proanthocyanadin, vitamin, mineral, melatonin, herbal, cannabis, tea,
coffee, cola drinks, pyridoxine, vitamin, mineral, ascorbic acid,
ascorbate, B6, anxiety, neurosis, depression, post-traumatic stress
disorder, Alzheimer's, dementia, cognitive deterioration, premenstrual
syndrome, PMS, panic, eating disorders, migraine, schizophrenia, bipolar
illness, manic, depression, mania, temporal lobe dysfunction, phobia,
pervasive developmental disorder, PDD, autism, obsessive compulsive
disordor, psychosis, refractory conditions, narcolepsy, drug abuse,
alcoholism, extrasensory perception, ESP, delta, psi, afferent, efferent,
subjective, vortex, paranormal, psychic, psychokinesis, PK, out of body
experience, OOBE, OBE, near death experience, NDE, survival, veridical,
dream, telepathy, clairvoyance, precognition, retrocognition, mediumship,
ectoplasm, aura, psychometry, remote viewing, Ganzfeld, deja entendu,
geomagnetic, deja pense, deja senti, deja pressenti, anomalous,
spontaneous, reincarnation, forced choice, Zener cards, experient,
non-experient, altered state, consciousness, phenomenologic">

<LINK REL="stylesheet" TYPE="text/css" HREF="../../../styles.css">

<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">

<script language="JavaScript" type="text/JavaScript">
<!--
function MM_displayStatusMsg(msgStr) { //v1.0
  status=msgStr;
  document.MM_returnValue = true;
}
//-->
</script>
<!-- InstanceBeginEditable name="head" --><!-- InstanceEndEditable -->
</head>

<body text="#000000" link="#990000" vlink="#990000" alink="#990000" onLoad="MM_displayStatusMsg('PNI.org | Pacific Neuropsychiatric Institute');return document.MM_returnValue">
<a name="top"></a> 
<table width="700" border="1" align="center" cellpadding="0" cellspacing="0" bordercolor="#000000">
  <tr> 
    <td><table width="100%" border="0" cellpadding="0" cellspacing="0" bgcolor="C4D2FF">
        <tr> 
          <td><a href="/"><img src="../../../header.jpg" width="700" height="127" border="0"></a></td>
        </tr>
        <tr>
          <td>
		  <div align="right">
				<a href="http://brainvoyage.com/">www.brainvoyage.com</a>
				 | <a href="http://vernonneppe.org/">www.vernonneppe.org</a>
				 | <a href="http://vernonneppe.com/">www.vernonneppe.com</a>
				 | <a href="http://ecao.us/">www.ecao.us</a>&nbsp;
			</div>
			<div align="left" >
				<script>
				  (function() {
					var cx = '009175660163571863627:du9tocqgd6q';
					var gcse = document.createElement('script');
					gcse.type = 'text/javascript';
					gcse.async = true;
					gcse.src = 'https://cse.google.com/cse.js?cx=' + cx;
					var s = document.getElementsByTagName('script')[0];
					
					s.parentNode.insertBefore(gcse, s);
				  })();
				</script>
				<gcse:search></gcse:search>
			</div>
			<table width="100%" border="0" cellspacing="0" cellpadding="15">
              <tr>
                <td width="100%"><p><font size="3" face="Arial, Helvetica, sans-serif"><strong>
                    <a href="http://pni.org/neuropsychiatry/">NEUROPSYCHIATRY and BEHAVIORAL NEUROLOGY</a>
                     | 
                    <a href="http://pni.org/psychopharmacology/">PSYCHOPHARMACOLOGY</a><br><a href="http://pni.org/forensics/">FORENSICS</a> | <a href="/research/">RESEARCH</a>
					 | 
                    <a href="http://pni.org/consciousness/">CONSCIOUSNESS</a>
					 | 
                    <a href="http://pni.org/philosophy/">PHILOSOPHY</a> | <a href="http://www.brainvoyage.com/ctbm/">BOOKS</a> | <a href="/books/">LITERATURE</a><br>
                    <a href="http://pni.org/perspective.html">PERSPECTIVES</a>
                    | <a href="http://pni.org/clinical/">CLINICAL</a> | <a href="http://pni.org/research/anomalous/deja/">D&Eacute;J&Agrave; VU</a> | 
                    <a href="http://pni.org/interesting/">INTERESTING AREAS</a> | <a href="http://pni.org/philosophy/ethics/">ETHICS</a>
                    | <a href="http://pni.org/about_pni.html">CONTACT</a></strong></font></p>
                <p>
					<strong>
						KEY ARTICLES:
						<a href="http://www.pni.org/neuropsychiatry/consciousness/">CONSCIOUSNESS</a> | 
						<a href="http://pni.org/key-articles/double-blind.html">DOUBLE BLIND</a> | 
						<a href="http://pni.org/neuropsychiatry/chit/">HEAD INJURY</a> | 
						<a href="http://pni.org/neuropsychiatry/narcolepsy/">NARCOLEPSY</a> | 
						<a href="http://www.pni.org/neuropsychiatry/paroxysmal/">PAROXYSMAL DISORDERS</a> | 
						<a href="http://pni.org/psychopharmacology/principles/">PRESCRIPTION PRINCIPLES</a> | 
						<a href="http://www.pni.org/neuropsychiatry/tardive_dyskinesia/">TARDIVE DYSKINESIA</a> |
						<a href="http://www.pni.org/neuropsychiatry/moral_philosophy/">MORAL PHILOSOPHY</a> | 
						<a href="http://pni.org/key-articles/deja-vu.html">DEJA VU</a>
						</strong>
						<p>
					<strong>
						Enduring Interest: </strong>
						<a href="http://www.pni.org/psychopharmacology/generics">Generic Substitution</a> | 
						<a href="http://www.pni.org/intelligence/">Genius</a> | 
						<a href="http://www.pni.org/groundbreaking/">Groundbreaking Paradigm Shifts</a> | 
						<a href="http://www.pni.org/ethics/security/">Zmail</a> |
						<a href="http://www.pni.org/philosophy/">Philosophy</a>
					
				</td>
              </tr>
            </table>
            <table width="100%" border="0" cellspacing="0" cellpadding="0">
              <tr> 
                <td class="bodyText" valign="top"><!-- InstanceBeginEditable name="content" -->
                  <p> </p>
                  <p align="center"></p>
                  <table width="650" border="0" align="center" cellpadding="5" cellspacing="0">
                    <tr> 
                      <td width="74%" valign="top"><div align="center"> 
                          <H1>Attention Deficit Disorder, Irritability and Serotonin 
                            1 A Neuromodulation </H1>
                          <P>Vernon M Neppe MD, PhD</P>
                          <H2>Educational Objectives</H2>
                          <OL>
                            <LI>
                              <div align="left"> To educate in the areas of attention 
                                deficit hyperactivity disorder and irritability 
                                in children and adolescents. </div>
                            </LI>
                            <LI>
                              <div align="left"> To present early information 
                                on the use of the azapirone compounds alone or 
                                as adjunct in ADHD and </div>
                            </LI>
                            <LI>
                              <div align="left"> To link aggression and ADHD with 
                                the serotonin 1A receptor and show the limitations 
                                of this approach. </div>
                            </LI>
                          </OL>
                          <P align="left"> Attention deficit hyperactivity disorder 
                            (ADHD) patients often present with school or behavioral 
                            problems linked with difficulty concentrating / distractibility 
                            and an impulsivity manifesting often as irritability 
                            and low frustration tolerance (3%-5% of children with 
                            75%-90% males). Hyperactivity is marked in three quarters 
                            of these patients. Subtle organic cerebral deficits 
                            are common (a quarter). Biochemically psychostimulants 
                            commonly diminish hyperactivity. Disputably up to 
                            half such patients have emotional problems at home 
                            sometimes secondary to the ADHD, leading to a heterogeneity 
                            of diagnosis for the condition. A common scale for 
                            measurement is the Connors Teacher and Parent Scale 
                            particularly an abbreviated version, where the cutoff 
                            score of 15 on 10 special items (each ordinally ranked 
                            0 to 3) for ADHD is traditional. </P>
                          <P align="left"> Psychostimulants such as methyl-phenidate 
                            (Ritalin) (Schedule 2) or pemoline (Cylert) (Sched 
                            4) are the most common treatments for ADHD but are 
                            not benign agents. Their mechanism is poorly understood, 
                            linked with dopamine and "paradoxical" effects on 
                            the reticular activating system. Dependence problems 
                            may occur particularly in other family members. Poorly 
                            controlled patients have received adjunctive or alternative 
                            therapies to the psychostimulants such as tricyclic 
                            antidepressant (e.g. imipramine, phenothiazines e.g. 
                            thioridazine and clonidine) with limited success or 
                            potential accentuation of side-effects. </P>
                          <P align="left"> A significant ADHD symptom that is 
                            commonly poorly controlled with psychostimulants is 
                            irritability. This suggests that at least in this 
                            subpopulation a partially different biochemical mechanism 
                            is involved. Exploration of aggression spectrum concepts 
                            such as anger, aggression, hostility, irritability 
                            and impulsivity are compromised by the general equivalent 
                            use of these terms, measuring difficulties, lack of 
                            research in the area and particularly no current diagnostic 
                            framework for aggression in DSM 3R or DSM-IV, with 
                            consequently no FDA approved drugs for aggression. 
                            All treatments being therefore innovative psychopharmacotherapy. 
                          </P>
                          <P align="left"> Evidence exists for serotonin receptor 
                            involvement in the aggression spectrum using animal 
                            models and human studies (clinical and post-mortem). 
                            The serotonin 1A receptor is promising using non-specific 
                            models such as lithium carbonate, beta-adrenergic 
                            blocking agents and benzodioxines. The only selective 
                            group for serotonin 1A in therapeutic doses is the 
                            azapirones. Animal models suggest the azapirones are 
                            potent anti-aggressive agents. This should be via 
                            their specific serotonin 1A partial agonist effects 
                            at postsynaptic doses or specific full agonist effects 
                            at the autoreceptor level in lower doses. The only 
                            currently marketed azapirone is buspirone. Irritability 
                            is an early target symptom of response with buspirone 
                            in generalized anxiety disorder possibly implying 
                            persistent low-dose effects. Moreover, buspirone improves 
                            concentration. </P>
                          <P align="left"> <I>Preliminary</I> open experience 
                            by Neppe suggests a biphasic dose effect for buspirone: 
                            Low dose buspirone (5-25 mg per day) was effective 
                            after a few days in alleviating irritability, anger 
                            and hostility without associated significant anxiety 
                            (N&gt;50); higher doses such as 60-90 mg per day almost 
                            immediately greatly relieved manic irritability, agitation, 
                            restlessness and mood lability (N=12). This data requires 
                            adequate controlled studies. Ratey's work is similar 
                            but in mental retardates. McCormick, 1994 found 9/10 
                            children improved in a short (2 weeks buspirone), 
                            randomized double-blind crossover ADHD study of buspirone 
                            alone in very low doses (5mg q8am and q11am on weekdays) 
                            versus placebo, using the 10 point abbreviated Connors 
                            rating scale. </P>
                          <P align="left"> In our large open pilot study in Reno, 
                            Nevada led by Dr Zo Young, buspirone was hypothesized 
                            to improve ADHD target symptoms such as irritability 
                            and concentration (N=40). Children and adolescents 
                            (aged 5-15 years at entry and mainly males) in DSM3R 
                            ADHD patients with Connors scores of &gt;15 who had 
                            only partly responded to psychostimulant received 
                            <I>buspirone</I> (usually 10mg tid; range 10-45mg 
                            /day) as <I>adjunct</I> to conventional doses of <I>methyl-phenidate</I> 
                            (usually 10-20mg tid) or rarely <I>pemoline</I> (37.5 
                            mg bid or tid). </P>
                          <P align="left"> Buspirone clinically improved several 
                            target symptoms: <I>concentration / distractibility 
                            / school functioning</I>; <I>irritability / anger 
                            / temper tantrums / low frustration tolerance</I>. 
                            Additionally these children, improved in <I>sleep 
                            disturbance</I> and where present anxiety or anxiety-depression. 
                          </P>
                          <P align="left"> A <I>further population of aggressive 
                            non-ADHD</I> children also responded well to <I>buspirone 
                            alone</I> in similar doses (ultimately 20/27). Because 
                            of the open, clinical nature of the study, statistics 
                            have limited meaning but relevant clinical improvements 
                            ostensibly occurred in &gt; 90% of ADHDs and 74 % 
                            of non-ADHD patients. Efficacy occurred within a week 
                            but took &gt;four weeks for full effects. Follow-up 
                            periods have been up to 5 years with no loss of efficacy. 
                            The buspirone was well tolerated. Overall, side-effects 
                            were reported only rarely (&lt;6% usually dizziness. 
                            Further clinical study, suggests <I>buspirone alone</I> 
                            does not apparently improve hyperactivity (N=5) again 
                            suggesting a special functional limitation for serotonin 
                            1A probes. </P>
                          <P>
                            <MULTICOL COLS=2>
                            </MULTICOL>
                          </P>
                          </div>
                        <P align="right"><font face="Arial, Helvetica, sans-serif"><a href="#top"><img src="../../../top.gif" width="48" height="19" border="0"></a></font></P></td>
                    </tr>
                  </table>
                  <p>&nbsp;</p>
                  <!-- InstanceEndEditable --> 
                  <p>&nbsp;</p>
				  </td>
              </tr>
            </table>
            
          </td>
        </tr>
        <tr>
          <td height="29"><img src="../../../bottom.jpg" width="700" height="29" border="0" usemap="#Map3"></td>
        </tr>
      </table></td>
  </tr>
</table>
<p align="center"><br>
  <font size="2" face="Arial, Helvetica, sans-serif">Copyright &copy;1997-2018 
  Pacific Neuropsychiatric Institute</font><br>
</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<map name="Map3">
  <area shape="rect" coords="237,3,385,23" href="http://pni.org/about_pni.html">
  <area shape="rect" coords="410,5,566,25" href="http://www.pni.org/disclaimer.html">
  <area shape="rect" coords="582,3,682,26" href="http://www.pni.org/credits.html">
</map>
</body>
<!-- InstanceEnd --></html>
